Current Clinical Trials

Phase I Study of the safety, Pharmacokinetic and Pharmacodynamic Properties of Intravenously Administered APG-1252 in Patients with Small Cell Lung Cancer (SCLC) or other Solid Tumors

Phase I, dose escalation study of ALX148 in patients with advanced solid tumors or lymphoma examining safety, pharmacokinetics and tolerability. NOW IN COMBINATION PHASE II WITH PEMBROLIZUMAB, RITUXIMAB AND TRASTUZUMAB

A Phase Ia/IIa Cohort Dose Escalation Trial to Determine the safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of AVID100, an Anti-Human Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Linked to the Maytansinoid DM1 in Patients with Advanced or Metastatic Solid Tumors of Epithelial Origin.

A Phase I Cohort Dose-Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of AVID 200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients with Advanced or Metastatic Solid Tumor Malignancies

A Phase Ib Study to Assess the Safety, Tolerability, and Clinical Activity of BGB-290 in Combination with Temozolomide (TMZ) in Subjects with Locally Advanced or Metastatic Solid Tumors

A Phase I/II, First-in-Humans, Open-Label, Dose-Escalation Study of MGC018 (Anti-B7-H3 Antibody Drug Conjugate) Alone and in Combination with MGA012 (Anti-PD-1 Antibody) in Patients with Advanced Solid Tumors

A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Stage I-III Limited Disease Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Principle Investigator: Dr. Chen

A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in adult patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

Principle Investigator: Dr. Chen

RESILIENT: A Randomized, Open Label Phase III Study of Irinotecan Liposome Injection (ONIVYDE®) versus Topotecan in Patients with Small Cell Lung Cancer Who Have Progressed on or after Platinum-based First-Line Therapy

Principle Investigator: Dr. Chen

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Primary Investigator: Dr. O’Rourke

Expanded access to mepolizumab for patients with hypereosinophilic syndrome

Principal Investigator: Dr. Gribbin

A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant

Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed

Prevalence of PD-L1 Expression in Patients With Advanced Urothelial Carcinoma

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation

Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer

A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men with Metastatic Castration-resistant Prostate Cancer.

Principle Investigator: Dr. Batts

Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors from twelve primary cancer diagnoses: breast, lung, colorectal, prostate, bladder, uterine, kidney and renal pelvis, pancreatic, liver, stomach, ovarian, esophageal

Principle Investigator: Dr. Chandana

A Phase II, Multicenter, Open-label, Safety and Efficacy Study of Xermelo plus First-line Chemotherapy (Cis/Gem) in Patients with Locally Advanced, Unresectable, Recurrent or Metastatic Biliary Tract Cancer (BTC).

Principle Investigator: Dr. Chandana